GlassScriptPhysician profile
Bruce D Scully
NPI 1366437972
$7,877.81
in general payments reported to CMS, 2019-2025
49 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,165 · 2020: $498 · 2021: $1,799 · 2022: $2,540 · 2023: $649 · 2024: $104 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $875 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $874.55 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,670.03 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $873.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $532.67 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $510.10 | 2019-2023 | Jardiance |
| Amgen INC. | $341.19 | 2019-2023 | Evenity, Prolia |
| Pfizer INC. | $333.35 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $268.06 | 2019-2023 | Rexulti |
| Lilly USA, LLC | $262.83 | 2019-2025 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $262.71 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $257.51 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $170.41 | 2021-2022 | |
| Astellas Pharma US INC | $164.48 | 2019-2020 | |
| Abbott Laboratories | $154.80 | 2022-2023 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $148.31 | 2019-2023 | Xarelto |
| Antares Pharma, INC. | $141.88 | 2019-2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Scully listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.